4142:TPE
Adimmune Corp
NT$16.80
arrow_upward
+0.60%(+0.100) 1D
Nov 13, 1:30:11 PM GMT+8 · TWD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4142...
Open
NT$16.85
High
NT$17.15
Low
NT$16.75
Mkt. cap
7.22B
Avg. vol.
1.13M
Volume
724.64K
52-wk high
NT$22.50
52-wk low
NT$15.65
EPS
-NT$0.34
Shares outstanding
235.29M
No. of employees
564
Open
NT$16.85
High
NT$17.15
Low
NT$16.75
Mkt. cap
7.22B
Avg. vol.
1.13M
Volume
724.64K
52-wk high
NT$22.50
52-wk low
NT$15.65
EPS
-NT$0.34
Shares outstanding
235.29M
No. of employees
564
News stories
From web sources and news partners
BigGo Finance
·
4 hours ago
Goldman Sachs Sets 8,700 S&P 500 Target for 2027, Sees 14% Upside as AI Capex Peaks
The Motley Fool
·
3 hours ago
Tesla Is Down 13% in 2026 While the S&P 500 Is Up. Here’s the 1 Catalyst Left This Year That Could Flip That.
24/7 Wall St.
·
2 hours ago
Gilead Beat the S&P 500 by More Than 25 Points in the Past Year, but $1,000 From a Decade Ago Is Still Worth Less Than $3,500
Traders Union
·
2 hours ago
Chris Ciovacco: Semiconductors SMH and S&P 500 SPY show several possible support areas
Profile
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
About Adimmune Corp
CEO-
Employees564
Founded1965
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteadimmune.com.tw